WO2008021745A3 - Hepatitis c virus entry inhibitors - Google Patents

Hepatitis c virus entry inhibitors Download PDF

Info

Publication number
WO2008021745A3
WO2008021745A3 PCT/US2007/075110 US2007075110W WO2008021745A3 WO 2008021745 A3 WO2008021745 A3 WO 2008021745A3 US 2007075110 W US2007075110 W US 2007075110W WO 2008021745 A3 WO2008021745 A3 WO 2008021745A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
entry inhibitors
virus entry
virus
hcv
Prior art date
Application number
PCT/US2007/075110
Other languages
French (fr)
Other versions
WO2008021745A2 (en
Inventor
Timothy J Cuthbertson
Maureen Ibanez
Cornelis A Rijnbrand
Andrew Jeremiah Jackson
Gopi Kumar Mittapalli
Fang Zhao
James E Macdonald
Flossie Wong-Staal
Original Assignee
Itherx Pharmaceuticals Inc
Timothy J Cuthbertson
Maureen Ibanez
Cornelis A Rijnbrand
Andrew Jeremiah Jackson
Gopi Kumar Mittapalli
Fang Zhao
James E Macdonald
Flossie Wong-Staal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Itherx Pharmaceuticals Inc, Timothy J Cuthbertson, Maureen Ibanez, Cornelis A Rijnbrand, Andrew Jeremiah Jackson, Gopi Kumar Mittapalli, Fang Zhao, James E Macdonald, Flossie Wong-Staal filed Critical Itherx Pharmaceuticals Inc
Publication of WO2008021745A2 publication Critical patent/WO2008021745A2/en
Publication of WO2008021745A3 publication Critical patent/WO2008021745A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to the use of tricyclic diphenylamine derivative compounds for prevention and/or treatment of Hepatitis C virus (HCV) infection by inhibiting HCV entry into permissive cells.
PCT/US2007/075110 2006-08-16 2007-08-02 Hepatitis c virus entry inhibitors WO2008021745A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82261806P 2006-08-16 2006-08-16
US60/822,618 2006-08-16

Publications (2)

Publication Number Publication Date
WO2008021745A2 WO2008021745A2 (en) 2008-02-21
WO2008021745A3 true WO2008021745A3 (en) 2008-10-16

Family

ID=39082878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075110 WO2008021745A2 (en) 2006-08-16 2007-08-02 Hepatitis c virus entry inhibitors

Country Status (1)

Country Link
WO (1) WO2008021745A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080566B1 (en) 2008-06-11 2011-12-20 Kalypsys, Inc Carbazole inhibitors of histamine receptors for the treatment of disease
EP2391602B1 (en) 2008-12-19 2013-12-04 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
BRPI1006825A2 (en) 2009-01-09 2019-04-24 Univ Texas pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US20120039804A1 (en) * 2010-06-04 2012-02-16 Philippe Diaz Novel Tricyclic Modulators of Cannabinoid Receptors
EP2590647B1 (en) 2010-07-07 2017-11-08 Board of Regents of the University of Texas System Pro-neurogenic compounds
EP2598149A4 (en) * 2010-07-26 2014-09-10 Merck Sharp & Dohme Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
ITSA20110014A1 (en) * 2011-06-16 2012-12-17 Univ Degli Studi Salerno SUMMARY AND BIOLOGICAL ACTIVITY OF N-ALCHILCARBAZOL DERIVATIVES AS STAT3 INHIBITORS
CA2873895A1 (en) * 2011-08-24 2013-02-28 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
EP2748160A4 (en) * 2011-08-24 2015-01-14 Boehringer Ingelheim Int Hepatitis c inhibitor compounds
US9701676B2 (en) 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
CN104496938B (en) * 2014-11-28 2016-06-22 太仓运通生物化工有限公司 A kind of preparation method of 2-acetyl phenothiazine
ES2928164T3 (en) 2015-10-19 2022-11-15 Incyte Corp Heterocyclic compounds as immunomodulators
CA3005727A1 (en) 2015-11-19 2017-05-26 Incyte Corporation Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators
PE20230731A1 (en) 2015-12-22 2023-05-03 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
CN105523992A (en) * 2016-01-14 2016-04-27 上海马氏化学科技有限公司 General synthetic method for N-substituted carbazole dicarboxylic acid derivatives
AR108396A1 (en) 2016-05-06 2018-08-15 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
ES2905980T3 (en) 2016-05-26 2022-04-12 Incyte Corp Heterocyclic compounds as immunomodulators
PE20190731A1 (en) 2016-06-20 2019-05-23 Incyte Corp HETEROCICLICAL COMPOUNDS AS IMMUNOMODULATORS
ES2930092T3 (en) 2016-07-14 2022-12-07 Incyte Corp Heterocyclic compounds as immunomodulators
MA46045A (en) 2016-08-29 2021-04-28 Incyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
MY197635A (en) 2016-12-22 2023-06-29 Incyte Corp Benzooxazole derivatives as immunomodulators
ES2899402T3 (en) 2016-12-22 2022-03-11 Incyte Corp Pyridine derivatives as immunomodulators
US10639313B2 (en) 2017-09-01 2020-05-05 Ndsu Research Foundation Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation
EP3713920A4 (en) 2017-11-20 2021-04-14 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
US11414387B2 (en) 2017-11-20 2022-08-16 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
HRP20230090T1 (en) 2018-03-30 2023-03-17 Incyte Corporation Heterocyclic compounds as immunomodulators
CN108456166B (en) * 2018-04-19 2021-02-05 遂成药业股份有限公司 Method for synthesizing acridone acetic acid by adopting phase transfer catalysis method
CN112752756A (en) 2018-05-11 2021-05-04 因赛特公司 Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
AR120109A1 (en) 2019-09-30 2022-02-02 Incyte Corp PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS
PE20230407A1 (en) 2019-11-11 2023-03-07 Incyte Corp SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR
CN113024382A (en) * 2019-12-25 2021-06-25 同济大学 Monocyano-substituted polycarboxylic organic ligand and preparation method thereof
MX2023005362A (en) 2020-11-06 2023-06-22 Incyte Corp Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof.
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2590125A (en) * 1952-03-25 Quaternary-ammonium alkyl
US3268550A (en) * 1963-08-26 1966-08-23 Ibm Nu-butenyl carbazoles
US6071932A (en) * 1995-05-05 2000-06-06 British Technology Group Intercorporate Licensing Limited Carbazolypiperines as GABA uptake inhibitors
WO2002089810A1 (en) * 2001-05-07 2002-11-14 United States Army Medical Research And Materiel Command Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof
US6689784B2 (en) * 2000-03-29 2004-02-10 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2590125A (en) * 1952-03-25 Quaternary-ammonium alkyl
US3268550A (en) * 1963-08-26 1966-08-23 Ibm Nu-butenyl carbazoles
US6071932A (en) * 1995-05-05 2000-06-06 British Technology Group Intercorporate Licensing Limited Carbazolypiperines as GABA uptake inhibitors
US6689784B2 (en) * 2000-03-29 2004-02-10 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
WO2002089810A1 (en) * 2001-05-07 2002-11-14 United States Army Medical Research And Materiel Command Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators

Also Published As

Publication number Publication date
WO2008021745A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2008021745A3 (en) Hepatitis c virus entry inhibitors
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
WO2008021936A3 (en) Hepatitis c virus inhibitors
WO2007092888A3 (en) Hcv ns5b inhibitors
WO2008057995A3 (en) Hcv protease inhibitors
WO2008051477A3 (en) Hcv ns3 protease inhibitors
WO2008021927A3 (en) Hepatitis c virus inhibitors
MY164469A (en) Hcv ns3 protease inhibitors
EP1924593B8 (en) Hcv ns3 protease inhibitors
WO2008008776A3 (en) Hepatitis c virus inhibitors
MY186633A (en) Heterocyclic compounds as inhibitors of hepatitis c virus (hcv)
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2006119061A3 (en) Hcv ns3 protease inhibitors
WO2010075376A3 (en) Anti-viral compounds
WO2008060927A3 (en) Hepatitis c virus inhibitors
MX2012008443A (en) 4 ' - azido - nucleosides as anti - hcv compunds.
IL198741A0 (en) Hepatitis c virus inhibitor compounds, compositions containing the same and uses thereof
MX2011006631A (en) Hcv ns3 protease inhibitors.
IL196815A0 (en) Hepatitis c virus inhibitors
MX2012003170A (en) Heterocyclic antiviral compounds.
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07813721

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07813721

Country of ref document: EP

Kind code of ref document: A2